Not a cheerleader..not a basher..long as of this m
Post# of 145407
1. In many ways trial results nullify Patterson’s paper as double blind is the gold standard although Patterson’s paper would be a cherry on the sundae.
2. The only two milestones left are the severe trial and a BLA for...anything.
I hope the severe study nails it. Many people on this board have rightly pointed this out. I personally don’t believe being a little (?) better than current standard of care will be enough for FDA approval. Not saying it won’t happen but refuse to whistle in the dark.
![Like This Post](/images/thumb-up.png)
![Dislike This Post](/images/thumb-down.png)